Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07597772

Preliminary Trial of SNA014 for Pancreatic Cancer

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300000, China

Location status: Recruiting

Location contact

Tianjin Medical University Cancer Institute and Hospital

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18 and 75 years (inclusive);
  • Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
  • Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
  • Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
  • Pathology test results from within the past year;

Exclusion criteria

  • Patients with other clearly diagnosed malignant tumours;
  • Patients with uncontrolled severe infections, or those with other serious comorbidities;
  • Patients with a life expectancy of ≤3 months;
  • Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
  • Patients deemed unsuitable for participation in this study by the investigator.

Treatment and study plan

68Ga-NODAGA-SNA006

Drug

Administration

Primary outcomes

  1. The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.

    Time frame: 1 week

    Occurrence of AE/SAE according to CTCAE 5.0

  2. CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.

    Time frame: 1 week

    SUVmax of tumors

  3. CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.

    Time frame: 1 week

    SUVmean of tumors

  4. CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.

    Time frame: 1 week

    Correlation of tumor uptakes and Immunohistochemistry

Study contacts

Contact information is provided by the study sponsor or research team.

Dong Dai, Doctor

CONTACT

[email protected]

022-23340123

Sponsors and collaborators

Lead sponsor

SmartNuclide Biopharma

Industry

Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

Registry information

Official study title

A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 19, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.